Mechanism of Action of Semaglutide (Ozempic)
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to human GLP-1 that selectively binds to and activates GLP-1 receptors, stimulating glucose-dependent insulin secretion, suppressing glucagon release, and delaying gastric emptying. 1
Core Molecular Mechanism
Semaglutide functions through GLP-1 receptor activation, which triggers multiple downstream effects:
Pancreatic Effects (Glucose-Dependent)
- Stimulates insulin secretion from pancreatic β-cells by increasing intracellular calcium, leading to insulin exocytosis 2
- Suppresses glucagon secretion from α-cells when blood glucose is elevated 1
- This glucose-dependent mechanism explains the low hypoglycemia risk—when glucose is normal or low, these effects are attenuated 2
Gastric Effects
- Delays gastric emptying in the early postprandial phase by inhibiting gastric peristalsis and increasing pyloric tone 2, 1
- This effect is mediated through vagal pathways and reduces the rate at which glucose appears in circulation after meals 2
- Scintigraphy studies confirm delayed gastric emptying persists with chronic use, though some tachyphylaxis may occur with continuous exposure 2
Central Nervous System Effects
- Reduces appetite and food intake through GLP-1 receptors in the hypothalamus (arcuate nucleus) and brainstem (area postrema, nucleus tractus solitarius) 2
- These centers regulate energy intake, expenditure, and satiety signaling 2
Structural Modifications for Prolonged Action
The key to semaglutide's once-weekly dosing lies in three molecular modifications 1:
- Albumin binding via a C18 fatty di-acid chain attached at position 26—this is the principal protraction mechanism that decreases renal clearance and protects against metabolic degradation 1
- DPP-4 resistance through modification at position 8, preventing rapid enzymatic degradation 1
- Minor modification at position 34 to ensure single fatty acid attachment 1
These changes extend the half-life to approximately 1 week, compared to native GLP-1's 2-minute half-life 2, 1.
Clinical Pharmacodynamics
At steady state (after 12 weeks at 1 mg dose), semaglutide produces 1:
- 22% reduction in fasting glucose (29 mg/dL absolute decrease)
- 36% reduction in 2-hour postprandial glucose (74 mg/dL decrease)
- 8% reduction in fasting glucagon
- 14-15% reduction in postprandial glucagon response
Cardiovascular and Renal Benefits
Beyond glycemic control, semaglutide demonstrates cardiovascular and kidney benefits independent of glucose lowering 3. The 2025 ADA Standards recommend semaglutide as a first-line agent for people with CKD based on dedicated kidney outcome trials showing beneficial effects on CVD, mortality, and kidney outcomes 3.
Important Clinical Considerations
- Bioavailability: 89% for subcutaneous administration; absorption is similar regardless of injection site (abdomen, thigh, upper arm) 1
- No dose adjustment needed for renal or hepatic impairment 1
- The glucose-lowering effect is preserved across all levels of kidney function, unlike SGLT2 inhibitors whose efficacy declines below eGFR 45 mL/min/1.73 m² 3
- During hypoglycemia, semaglutide does not impair counter-regulatory glucagon responses, maintaining protective mechanisms 1